Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a finding of wrongdoing. It is an investigation notice, and investors ought to treat it as such. Still, these notices usually circle the same uncomfortable terrain: Was the price adequate, was the sales process sturdy enough, and did insiders receive benefits that regular holders cannot touch?
A Warning Light, Not a Verdict
There is a whole cottage industry around merger challenges, and I have watched plenty of them produce extra disclosure, a few tweaks, or nothing much at all. Anybody telling shareholders that an investigation automatically means a bad deal is selling smoke. On the other hand, brushing it aside because it came from a shareholder-rights firm is lazy investing. The announced terms are where the real work begins.
Halper Sadeh says proposed transaction terms may limit superior competing offers and that insiders may receive substantial financial benefits unavailable to ordinary shareholders. Those are serious concerns in principle, but the notice does not provide deal-specific evidence showing either issue occurred at any one company. That distinction matters. Shareholders need the merger materials, the background of negotiations, the financial adviser analyses, and the disclosures around management compensation before making a reasoned call.
“May” is doing heavy lifting in this announcement; investors should demand documents before drawing conclusions.
Fulcrum’s Five Percent Question
For NASDAQ:FULC, the stated transaction is a merger with Slate Medicines. Upon closing, Fulcrum shareholders are expected to own 5.0% of the combined company. That is a small slice, plain and simple, and it puts the focus squarely on what those holders are receiving in exchange for giving up their standalone stake.
A 5.0% ownership figure alone says nothing definitive about fairness. Maybe the combined company offers a more realistic route to financing, development, or commercialization. Maybe Fulcrum’s alternatives were thin. Maybe not. The missing details are the ones shareholders should care about: the valuation assigned to each side, projected ownership dilution beyond closing, the governance of the combined company, and whether Fulcrum had a meaningful chance to seek other paths. Biotech mergers can be brutally practical affairs, especially when capital needs loom, but practicality is not a free pass for weak disclosure.
Cash Offers Put Price Front and Center
NASDAQ:DSGR is slated to be sold to affiliates of LKCM Headwater Investments for $35.00 per share in cash. Cash deals are mercifully easier to frame than stock swaps. The question is not buried in an ownership percentage or some shiny presentation about future synergies: Is $35.00 per share a fair value relative to the company’s prospects and the process used to get there?
That does not mean shareholders should simply compare the offer with a recent trading price and call it a day. Markets can underprice a company for months, particularly when the outlook is messy or management has not earned much trust. Conversely, a premium can look handsome on paper while still being the best available outcome. Investors should look for the board’s explanation of the negotiations, any prior indications of interest, financial projections used by advisers, and deal protections that could discourage another bidder.
Option Care’s Price Needs Context Too
NASDAQ:OPCH is proposed to be sold to CD&R and McKesson Corporation for $32.05 per share. Again, the headline number is only the beginning. Option Care operates in a healthcare setting where scale, reimbursement dynamics, and strategic partnerships can matter greatly, but shareholders are not being asked to vote on a broad industry thesis. They are being asked, ultimately, whether the negotiated consideration reflects what they are surrendering.
McKesson’s involvement makes the strategic logic worth examining closely, while CD&R brings the familiar private-equity angle: sophisticated buyers generally do not spend time chasing assets they think are worthless. That is not proof the offer is too low; it is merely a reason not to accept the first neat narrative handed over by a boardroom.
Read the Proxy Before Picking a Side
Halper Sadeh says it may seek increased consideration, additional disclosures, or other relief on shareholders’ behalf, and says any representation would be on a contingent-fee basis. Investors considering their options should understand that prior results do not guarantee a similar outcome, as the firm itself notes.
- Read the merger proxy or equivalent filing when it becomes available.
- Compare management and director interests with those of ordinary shareholders.
- Inspect termination fees, no-shop terms, and any matching rights.
- Separate confirmed deal facts from allegations that remain unproven.
There is no need for theatrics here. These three situations deserve scrutiny because every public-company sale deserves scrutiny. The hard part is resisting both extremes: blind faith in the board and automatic outrage at the lawyers. Shareholders should demand a clean record, a credible explanation of price, and enough disclosure to judge whether these deals were truly earned rather than merely arranged.